APGE icon

Apogee Therapeutics

38.14 USD
-0.43
1.11%
At close Jul 11, 4:00 PM EDT
After hours
38.14
+0.00
0.00%
1 day
-1.11%
5 days
-19.31%
1 month
-10.13%
3 months
19.94%
6 months
-6.77%
Year to date
-19.11%
1 year
-16.96%
5 years
79.65%
10 years
79.65%
 

About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Employees: 196

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

57% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 21

50% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $9.54M

6% more funds holding

Funds holding: 157 [Q4 2024] → 167 (+10) [Q1 2025]

5.09% more ownership

Funds ownership: 128.52% [Q4 2024] → 133.61% (+5.09%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]

12% less capital invested

Capital invested by funds: $2.62B [Q4 2024] → $2.3B (-$320M) [Q1 2025]

14% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 58

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$116
204%
upside
Avg. target
$116
204%
upside
High target
$116
204%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Guggenheim
Seamus Fernandez
204%upside
$116
Buy
Reiterated
2 Jul 2025

Financial journalist opinion

Based on 5 articles about APGE published over the past 30 days

Positive
Seeking Alpha
5 days ago
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact, APG777 could potentially disrupt the massive AT market, which is currently dominated by Dupixent. APGE's Phase 2 trial, called APEX Part A, exceeded its targets. We also have to wait until 1H2026 for its maintenance data. Part B efficacy data is due by mid-2026.
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
Positive
Proactive Investors
6 days ago
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug
Apogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial met its primary endpoint with a 71% reduction in Eczema Area Severity Index (EASI) score at Week 16, versus 33.8% for placebo.
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug
Negative
Investors Business Daily
6 days ago
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
Neutral
GlobeNewsWire
6 days ago
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease  from baseline in EASI at Week 16
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
Neutral
GlobeNewsWire
1 week ago
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Neutral
GlobeNewsWire
1 month ago
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
Positive
Seeking Alpha
2 months ago
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034.
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class
Neutral
GlobeNewsWire
2 months ago
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Charts implemented using Lightweight Charts™